Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Details 詳細情報について

• CRID

  1364233270117491968

• DOI

  10.1016/s1470-2045(17)30171-7

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204517301717?httpAccept=text/plain

  https://api.elsevier.com/content/article/PII:S1470204517301717?httpAccept=text/xml

• Data Source

  • Crossref